Skip to main content
logo
Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ: KNSA · Real-Time Price · USD
44.71
-0.27 (-0.60%)
Feb 12, 2026, 4:00 PM EST - Market closed

KNSA Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
597.97423.24270.26220.1838.54-
Revenue Growth (YoY)
55.68%56.61%22.75%471.24%--
Cost of Revenue
282.33189.2289.9346.979.94-
Gross Profit
315.65234.02180.33173.2128.61-
Selling, General & Admin
180.03168.01129.4397.9585.9545.32
Research & Development
97.46111.6276.165.4999.3112.04
Operating Expenses
277.49279.63205.52163.44185.25157.36
Operating Income
38.15-45.62-25.29.77-156.64-157.36
Other Non Operating Income (Expenses)
10.479.468.541.250.11.13
Pretax Income
48.62-36.15-16.6511.03-156.54-156.23
Income Tax Expense
12.77.04-30.74-172.341.395.15
Net Income
35.92-43.1914.08183.36-157.92-161.38
Net Income to Common
35.92-43.1914.08183.36-157.92-161.38
Net Income Growth
---92.32%---
Shares Outstanding (Basic)
737170696962
Shares Outstanding (Diluted)
777172706962
Shares Change (YoY)
7.99%-0.69%2.13%2.69%10.89%14.42%
EPS (Basic)
0.49-0.600.202.64-2.30-2.61
EPS (Diluted)
0.47-0.600.202.60-2.30-2.61
EPS Growth
---92.31%---
Free Cash Flow
101.7325.4113.175.7-126.71-136.82
Free Cash Flow Per Share
1.330.360.180.08-1.85-2.21
Gross Margin
52.79%55.29%66.72%78.67%74.22%-
Operating Margin
6.38%-10.78%-9.32%4.44%-406.38%-
Profit Margin
6.01%-10.21%5.21%83.28%-409.72%-
Free Cash Flow Margin
17.01%6.00%4.87%2.59%-328.75%-
EBITDA
39.64-43.92-22.8612.18-154.28-154.96
EBITDA Margin
6.63%-10.38%-8.46%5.53%--
D&A For EBITDA
1.491.72.342.42.362.41
EBIT
38.15-45.62-25.29.77-156.64-157.36
EBIT Margin
6.38%-10.78%-9.32%4.44%--
Revenue as Reported
597.97423.24270.26220.1838.54-
Advertising Expenses
-11.439.075.73--
Updated Oct 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q